Valuation: HLS Therapeutics Inc.

Market Cap 79.25M 72M 66.52M 60.09M 113M 7.44B 117M 800M 317M 3.99B 297M 291M 12.65B P/E 2026 *
-12.6x
P/E 2027 * -24.4x
Enterprise Value 79.25M 72M 66.52M 60.09M 113M 7.44B 117M 800M 317M 3.99B 297M 291M 12.65B EV / Sales 2026 *
1.36x
EV / Sales 2027 * 1.22x
Free-Float
99.44%
Yield 2026 *
-
Yield 2027 * -
1 day+1.08%
1 week-14.19%
Current month-16.85%
1 month-8.54%
3 months-3.85%
6 months-17.22%
Current year-22.20%
1 week 3.51
Extreme 3.51
4.4
1 month 3.51
Extreme 3.51
4.69
Current year 3.51
Extreme 3.51
5.25
1 year 3.51
Extreme 3.51
5.25
3 years 3
Extreme 3
5.76
5 years 3
Extreme 3
18.21
10 years 3
Extreme 3
25.92
Manager TitleAgeSince
Chief Executive Officer 58 01/05/2023
Director of Finance/CFO 61 26/01/2024
Chief Tech/Sci/R&D Officer 61 01/06/2014
Director TitleAgeSince
Director/Board Member 58 12/03/2018
Chairman 48 22/06/2023
Director/Board Member 65 01/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
30/9/26 TaxCompany 1,000 0.0032% -
30/9/26 TaxCompany -1,000 0.0032% -
29/9/26 TaxCompany 2,000 0.0065% -
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%-14.19%-23.47%+5.63% 79.25M
-0.13%+2.23%+41.28%+145.17% 1,286B
-0.68%+0.76%+42.42%+89.37% 688B
+0.17%+0.88%+26.44%+113.97% 521B
+1.14%+2.04%+42.51%+72.81% 386B
-1.08%-1.57%+57.69%+43.57% 364B
+1.27%+1.72%+28.34%+63.11% 302B
+0.37%-0.23%+3.25%+38.05% 287B
-0.08%+0.22%+36.44%+73.32% 252B
+0.04%-0.30%+36.05%+126.54% 208B
Average +0.13%+0.28%+29.10%+77.15% 429B
Weighted average by Cap. -0.06%+3.26%+37.17%+99.28%

Financials

2026 *2027 *
Net sales 58.06M 52.75M 48.73M 44.02M 83.07M 5.45B 86M 586M 232M 2.93B 218M 213M 9.27B 64.8M 58.87M 54.39M 49.13M 92.71M 6.08B 95.98M 654M 259M 3.26B 243M 238M 10.34B
Net income -5.94M -5.4M -4.99M -4.51M -8.5M -558M -8.8M -60M -23.77M -299M -22.3M -21.83M -949M -2.91M -2.65M -2.44M -2.21M -4.17M -273M -4.31M -29.39M -11.65M -147M -10.93M -10.69M -465M
Net Debt - -
Projected Income Statement - Annual - HLS Therapeutics Inc.
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
17/11/26 CAD 3.750 +1.08% 49,411
13/11/26 CAD 3.710 +0.27% 172,776
12/11/26 CAD 3.700 -11.69% 89,830
11/11/26 CAD 4.190 +0.96% 37,125
10/11/26 CAD 4.150 -5.03% 33,069
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - HLS Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.603USD
Average target price
5.146USD
Spread / Average Target
+97.69%